Barinthus Biotherapeutics
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages)
|
 | |
| Company type | Public |
|---|---|
| Nasdaq: BRNS | |
| Industry | |
| Founded | 2016 |
| Founder | |
| Headquarters | , United Kingdom |
| Website | barinthusbio |
Barinthus Biotherapeutics plc is a biotechnology company developing immunotherapies for infectious diseases, cancer and autoimmune diseases such as hepatitis B, HPV and prostate cancer.[1][2] Formerly known as Vaccitech plc, in November 2023 the company announced that it had renamed itself to Barinthus Biotherapeutics plc.
Technology[edit]
The company's platforms include Chimpanzee Adenovirus Oxford (ChAdOx) and Modified vaccinia Ankara (MVA), two viral vectors which safely mimic viral infection in human cells and elicit antibody and T cell responses to pathogens and tumours,[3] as well as two SNAP synthetic platforms, SNAP-TI (SNAP-Tolerance Immunotherapy) and SNAP-CI (SNAP-Cancer Immunotherapy), previously referred to collectively as SNAPvaxTM.
History[edit]
The company was founded in 2016 as a University spin-off by Sarah Gilbert and Adrian V. S. Hill at The Jenner Institute, University of Oxford.[4][5][6]
Vaccitech has been financed and supported by M&G Catalyst, Google Ventures (GV), Fosun International, Tencent, Huawei, Sequoia Capital, GeneMatrix, Liontrust Asset Management, Korea Investment Partners and Oxford Sciences Innovation (OSI).[7][8][9]
In early 2020, Vaccitech and the University of Oxford co-invented a vaccine for COVID-19 using the ChAdOx platform.[citation needed]
COVID-19 vaccine[edit]
In July 2020, it was reported that people in Brazil, South Africa and the US had been recruited to populate the vaccine trials.[10]
In July 2020, Vaccitech scientists reported in The Lancet a "single-blind, randomised controlled trial in five trial sites in the UK of a chimpanzee adenovirus-vectored vaccine (ChAdOx1 nCoV-19) expressing the SARS-CoV-2 spike protein." Several subjects needed prophylactic paracetamol to minimize their adverse reactions.
Listing on NASDAQ[edit]
Vaccitech held an initial public offering of shares in 2021, listing on NASDAQ on 30 April 2021.[11]
References[edit]
- ^ Barinthus Biotherapeutics on Twitter
- ^ Anon (2016). "Vaccitech Limited". companieshouse.gov.uk. London: Companies House.
- ^ Anon (2019). "Vaccitech - Creating ways to treat and prevent disease". vaccitech.co.uk. Vaccitech Limited.
- ^ Anon (2019). "Vaccitech Ltd". bloomberg.com. Bloomberg News.
- ^ Anon (2016). "Universal flu vaccine under development by Oxford spinout Vaccitech". ox.ac.uk. University of Oxford.
- ^ Anon (2019). "Vaccitech secures £20m Series A with GV, OSI and Sequoia China". innovation.ox.ac.uk. Oxford University Innovation.
- ^ Anon (2019). "About Vaccitech". vaccitech.co.uk. Vaccitech Limited.
- ^ "Inside the Chinese companies developing a Covid-19 vaccine". The Week. 3 September 2020.
- ^ Anon (2021). "M&G leads $168 million Vaccitech financing". mandgplc.com. M&G plc.
- ^ Boseley, Sarah (1 July 2020). "Oxford offers best hope for Covid-19 vaccine this year, MPs told". Guardian News & Media Limited.
- ^ "Vaccitech prices shares at IPO". Reuters. 30 April 2021.
